Asset Details
Do you wish to reserve the book?
Dexamethasone loaded DNA scavenger nanogel for systemic lupus erythematosus treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dexamethasone loaded DNA scavenger nanogel for systemic lupus erythematosus treatment
Do you wish to request the book?
Dexamethasone loaded DNA scavenger nanogel for systemic lupus erythematosus treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dexamethasone loaded DNA scavenger nanogel for systemic lupus erythematosus treatment
2025
Overview
Lupus nephritis (LN) poses a severe risk for individuals with systemic lupus erythematosus (SLE), prompting extensive research into targeted delivery systems capable of modulating immune responses and clearing cell-free DNA (cfDNA). Here, we propose a novel renal homing nanogel that acts as a cfDNA scavenger and a dexamethasone (DXM) delivery carrier for LN treatment. Based on the generation 3 polylysine dendrimers, the created cationic nanogels (G3DSP) exhibit minimal toxicity and outstanding DXM loading efficiency. Our studies confirm that these nanogels can competitively bind with anionic cfDNA in vitro, leading to the suppression of toll-like receptor 9 (TLR9) activation. When administered systemically to MRL/lpr mice, the nanogels preferentially localize to and are retained in the inflamed kidneys, releasing their payload in response to reactive oxygen species (ROS), therefore effectively ameliorating SLE symptoms. Consequently, G3DSP nanogels emerge as a promising effective combined therapy for LN, minimizing cfDNA accumulation in vital organs and delivering immunomodulatory benefits through DXM.
[Display omitted]
•The nanogel specifically targets LN by acting as a scavenger for cfDNA and delivering DXM directly to the affected areas.•The polylysine nanogel exhibits minimal toxicity and demonstrates high efficiency in delivering DXM to the targeted sites.•By competitively binding with cfDNA, the nanogel effectively suppresses TLR9 activation and modulates immune responses.
